SYRE
Spyre Therapeutics
October 6, 2026 · intraday
- Rarity
- 2.01
- Peak move
- −13.70%
- Float cap
- $5.9B
Spyre Therapeutics is a clinical-stage biotechnology company developing long-acting, extended half-life monoclonal antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated conditions. Its pipeline targets the α4β7, TL1A, IL-23 and IL-17A/F pathways, tested as monotherapies and in combinations in ulcerative colitis and Crohn's disease, with additional programs in rheumatic diseases such as rheumatoid and psoriatic arthritis. It has no approved products or commercial revenue.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
7 events · 0 from SEC or newswire · 0 timed with the moveequity_offeringSpyre Therapeutics priced an underwritten public offering of 4,117,648 common shares at $85.00 per share for gross proceeds of about $350.0 million, with a 30-day underwriter option for up to 15% more, or roughly $52.5 million, closing on or about October 7, 2026.
equity_offeringSpyre Therapeutics commenced an underwritten public offering of its common stock, with underwriters granted a 30-day option for an additional 15% of the shares, managed by Jefferies, TD Cowen, Leerink Partners and Stifel as joint book-running managers.
insider_saleSpyre Therapeutics disclosed 20 insider transactions on October 2, 2026, including officer Heidy King-Jones acquiring 28,900 shares and sales by CEO Cameron Turtle and CFO Scott Burrows on October 1, 2026.
insider_saleSpyre Therapeutics CFO Scott L. Burrows sold 25,000 common shares for about $2.26 million across September 30 and October 1, 2026, after exercising options at $14.50 per share, leaving him 79,762 shares.
insider_saleSpyre Therapeutics CEO Cameron Turtle sold 100 shares of common stock at $93.91 per share on October 1, 2026, leaving him 537,540 shares directly held, per a Form 144 notice disclosed October 2, 2026.
insider_saleSpyre Therapeutics CFO Scott L. Burrows reported a change in beneficial ownership of the company's securities in an SEC Form 4 filing dated October 2, 2026.
insider_saleSpyre Therapeutics CEO and director Cameron Turtle sold 15,000 common shares on October 1, 2026 at weighted average prices of $89.14 to $93.91, disclosed in a Form 4 filed October 2 under a Rule 10b5-1 plan adopted June 20, 2025.